Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Personalization of Cancer Treatment: Exploring the Role of Chronotherapy in Immune Checkpoint Inhibitor Efficacy.
Cancers (Basel)
February 2025
Department of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA.
In the era of precision medicine, mounting evidence suggests that the time of therapy administration, or chronotherapy, has a great impact on treatment outcomes. Chronotherapy involves planning treatment timing by considering circadian rhythms, which are 24 h oscillations in behavior and physiology driven by synchronized molecular clocks throughout the body. The value of chronotherapy in cancer treatment is currently under investigation, notably in the effects of treatment timing on efficacy and side effects.
View Article and Find Full Text PDFIndividualized Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administration in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Nurse's Role.
J Infus Nurs
March 2025
Author Affiliations: Takeda Development Center Americas, Inc., Cambridge, Massachusetts (Kim Duff); IQVIA Clinical Research Organization, Milan, Italy (Arianna Soresini); IQVIA Clinical Research Organization, Cambridge, Massachusetts (Nancy Wolf* and Alane Fairchild); IQVIA Clinical Research Organization, Ankara, Turkey (Şükran Altan**); IQVIA Clinical Research Organization, Mexico City, Mexico (Wendy Bencomo); University Clinical Center of Serbia, Belgrade, Serbia (Ivana Ivankovic); University Health Network, University of Toronto, Toronto, Ontario, Canada (Evelyn Sarpong); IQVIA Clinical Research Organization, Warsaw, Poland (Anna Kuczkowska).
Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% offers potential improvements in patient independence and tolerability versus intravenous immunoglobulin (IVIG) when used for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). fSCIG 10% also requires less frequent infusions and fewer infusion sites than conventional subcutaneous immunoglobulin (subcutaneous immunoglobulin without hyaluronidase). The ADVANCE-CIDP 1 study demonstrated fSCIG 10% efficacy and safety in preventing CIDP relapse and positive responses from patients in terms of satisfaction and treatment preference.
View Article and Find Full Text PDFOutcomes of Cooled Radiofrequency Ablation of Lumbar Nerves as Treatment for Chronic Low Back Pain.
Pain Ther
March 2025
Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, B6/319 CSC, Madison, WI, 53792-3272, USA.
Introduction: Worldwide, 23% of adults suffer from chronic lower back pain, which is defined as pain persisting for more than 3-6 months [Merskey in Can J Psychiatry 34:329-336, 1989]. The lifetime prevalence of back pain is as high as 84% in adults [Casiano VE, Sarwan G, Dydyk AM, et al. Back Pain.
View Article and Find Full Text PDFAbrupt left coronary artery malperfusion secondary to acute type A aortic dissection after weaning from cardiopulmonary bypass: a case report.
BMC Cardiovasc Disord
March 2025
Department of Thoracic and Cardiovascular Surgery, Ewha Womans University Aorta and Vascular Hospital, Ewha Womans University Medical Center, Seoul, Korea.
Introduction: Acute Stanford type A aortic dissection (ATAAD) is a lethal emergency. However, even with instant surgical repair, early mortality is up to 20%. ATAAD complicated by coronary artery involvement is considered rare but life-threatening because this can cause coronary artery malperfusion which results in acute myocardial infarction.
View Article and Find Full Text PDFIntrainfusion Drug Monitoring and Algorithm-Based Dose Adjustments for Children With ALL Receiving High-Dose Methotrexate Are Feasible and Safe in Costa Rica, a Low- and Middle-Income Country.
JCO Glob Oncol
March 2025
Department of Pediatrics, Baylor College of Medicine, Houston, TX.
Purpose: Infusions of high-dose methotrexate at 5 g/m over 24 (HDMTX) as a single infusion for pediatric patients with high-risk precursor B-cell ALL are known to lead to superior outcomes. The Hospital Nacional de Niños Dr Carlos Sáenz Herrera, part of the public system Caja Costarricense de Seguro Social in Costa Rica (HNN), has been historically unable to provide this therapy secondary to the required intensive monitoring and cost-prohibitive toxicity support.
Methods: We report our experience providing HDMTX at HNN, to our knowledge, for the first time using an algorithm-based individualized HDMTX protocol designed to prevent toxic levels of methotrexate.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!